 |
 |
NHS Bath and North East Somerset, Swindon and Wiltshire CCG
Royal United Hospitals Bath NHS Foundation Trust
Great Western Hospitals NHS Foundation Trust
Salisbury NHS Foundation Trust
|
| Formulary Chapter 6: Endocrine system - Full Section
|
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
06.01 |
Drugs used in diabetes
(0,0)
|
|
06.01.01 |
Insulins
(0,0)
|
|
06.01.01.01 |
Short-acting insulins
(8,9)
|
|
06.01.01.02 |
Intermediate- and long-acting insulins
(9,5)
|
|
|
Biphasic insulins
(4,3)
|
|
06.01.01.03 |
Hypodermic equipment
(17,1)
|
|
06.01.02 |
Antidiabetic drugs
(0,0)
|
|
06.01.02.01 |
Sulphonyureas
(2,5)
|
|
06.01.02.02 |
Biguanides
(2,0)
|
|
06.01.02.03 |
Other antidiabetic drugs
(0,16)
|
|
|
Alpha glucosidase inhibitors
(0,1)
|
|
|
DPP4 inhibitors (gliptins)
(3,0)
|
|
|
GLP1 agonists
(8,1)
|
|
|
Meglitinides
(1,0)
|
|
|
SGL2 inhibitors
(5,0)
|
|
|
Thiazolidinediones
(1,0)
|
|
06.01.03 |
Diabetic ketoacidosis
(0,0)
|
|
06.01.04 |
Treatment of hypoglycaemia
(3,0)
|
|
|
Chronic hypoglycaemia
(1,0)
|
|
06.01.05 |
Treatment of diabetic nephropathy and neuropathy
(0,0)
|
|
06.01.06 |
Diagnostic and monitoring agents for diabetes mellitus
(0,0)
|
|
|
Blood glucose and blood ketone monitoring
(3,1)
|
|
|
Urinalysis
(3,0)
|
|
|
Oral glucose tolerance test
(1,1)
|
|
06.02 |
Thyroid and Antithyroid drugs
(0,0)
|
|
06.02.01 |
Thyroid hormones
(3,1)
|
|
06.02.02 |
Antithyroid drugs
(3,1)
|
|
06.03 |
Corticosteroids
(0,0)
|
|
06.03.01 |
Replacement therapy
(1,0)
|
|
06.03.02 |
Glucocorticoid therapy
(9,1)
|
|
|
Disadvantages of corticosteroids
(0,0)
|
|
|
Use of corticosteroids
(0,0)
|
|
|
Pregnancy and breastfeeding
(0,0)
|
|
|
Administration
(0,0)
|
|
|
Withdrawal of corticosteroids
(0,0)
|
|
06.04 |
Sex hormones
(0,0)
|
|
06.04.01 |
Female sex hormones and their modulators
(1,0)
|
|
06.04.01.01 |
Oestrogens and HRT
(17,1)
|
|
|
Ethinylestradiol
(1,0)
|
|
|
Raloxifene
(1,0)
|
|
|
Oestrogen only tablets
(0,0)
|
|
06.04.01.02 |
Progestogens
(6,1)
|
|
06.04.02 |
Male sex hormones and antagonists
(2,0)
|
|
|
Anti-androgens
(2,0)
|
|
06.04.03 |
Anabolic steroids
(0,0)
|
|
06.05 |
Hypothalamic and pituitary hormones and anti-oestrogens
(0,0)
|
|
06.05.01 |
Hypothalamic and anterior pituitary hormones and anti-oestrogens
(0,0)
|
|
|
Anti-oestrogens
(1,0)
|
|
|
Anterior pituitary hormones
(6,2)
|
|
|
Hypothalmic hormones
(2,0)
|
|
06.05.02 |
Posterior pituitary hormones and antagonists
(0,0)
|
|
|
Posterior pituitary hormones
(6,0)
|
|
|
Antidiuretic hormone antagonists
(2,1)
|
|
06.06 |
Drugs affecting bone metabolism
(0,0)
|
|
|
Osteoporosis
(0,0)
|
|
06.06.01 |
Calcitonin and parathyroid hormone
(1,1)
|
|
06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism
(0,0)
|
|
|
Bisphosphonates
(8,0)
|
|
|
Denosumab
(2,0)
|
|
|
Strontium renelate
(1,0)
|
|
06.07 |
Other endocrine drugs
(0,0)
|
|
06.07.01 |
Bromocriptine and other dopaminergic drugs
(3,0)
|
|
06.07.02 |
Drugs affecting gonadotrophins
(0,0)
|
|
|
Gonadorelin analogues
(6,1)
|
|
|
Breast pain (mastalgia)
(0,0)
|
|
06.07.03 |
Metyrapone
(1,0)
|
|
06.07.04 |
Somatomedins
(0,0)
|
|
|
|
